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Abstract  
The induction of gene mutation within a DNA sequence can result in an adverse impact, 
altering or preventing gene function. Therefore, in vitro evaluation of mutagenicity is an 
essential component of the toxicological screening process. A variety of mutagen screening 
tools are routinely used in genetic toxicology, which are based on selected reporter genes. 
These assays are however typically labour intensive and impractical for high throughput 
screening. Considering this, the IWGT (International Workshops on Genotoxicity Testing) sub-
group on Novel & Emerging In Vitro Mammalian Cell Mutagenicity Test Systems undertook a 
literature search to identify new approaches for mutation detection. This review therefore 
focused on identifying new approaches for mutation detection that have the potential for use 
as a future genotoxicity screening tool. A comprehensive literature review identified genome-
wide loss-of-function screening tools, next generation sequencing (NGS) mutation 
characterisation and fluorescence-based mutation detection methods as having significant 
promise as an emerging in vitro mammalian cell mutagenicity test system. Each of the 
technologies considered was assessed for its capacity to report on a wide array of heritable 
mutagenic changes, necessary to cover the full spectrum of genetic events imparted by 
substances with a broad range of modes of action. Of the technologies evaluated, NGS 
techniques exhibited the greatest advantages for use in a genotoxicity testing setting. 
However, it is important to note that the emerging techniques identified could not facilitate 
routine mutagenicity testing in their current format and require substantial additional 
optimisation and tailoring before they could be utilised as an in vitro mammalian cell 
mutagenicity test system. Additionally, new mammalian cell mutation test systems must be 
able to accurately and reliably detect and quantify rare events; hence any new system would 
require careful validation. Nevertheless, with further development emerging technologies 
such as NGS could become important in establishing more predictive and high-throughput 
regulatory hazard screening tools of the future.     
Highlights  
 Current mammalian in vitro mutagenicity assays are labour intensive and not high 
throughput 
 Emerging techniques require substantial development and optimisation 
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 Next generation sequencing offers huge potential in the mutagenicity testing arena 
 
Key words  
Gene mutation, Mutation reporter screen, Next generation sequencing, Haploid cells, 
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1. Introduction  
The past three decades have witnessed rapid and major advances in our understanding of the 
mechanistic aspects of mutagenesis at the molecular, biochemical, and cellular levels.  
Currently, it is economically feasible to get insights into DNA sequence variations at the single 
base-pair level of the entire genome among various samples and cohorts. The U.S. National 
Cancer Institute’s dictionary of cancer terms defines mutation as any change in the DNA 
sequence of a cell [1] . Thus, this review assumes that gene mutations are permanent 
alteration in the DNA sequence that may or may not have an adverse impact on the individual 
cell. Such alternations can vary from a single base-pair change to a large segment of the gene 
or multiple genes.  While some DNA sequence changes result in altered gene function, we 
currently do not have a full understanding of the impact of all possible genomic changes.  
The in vitro mammalian cell mutation assays currently in routine use for regulatory genetic 
toxicology were developed in 1970s and 80s.  These screens use selectable reporter genes 
such that cells with certain sequence changes (mutations) can grow and form colonies in the 
presence of a substance that is otherwise toxic to wild-type cells.  Examples of such tests 
include the OECD Test Guideline 476 and 490 In Vitro Mammalian Cell Gene Mutation Tests, 
based on mutation at thymidine kinase (TK) gene, hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) gene, and a transgene of xanthineguanine phosphoribosyl transferase 
(XPRT). These mammalian cell assays are labour and time intensive and not readily amenable 
to high throughput screening.  Most importantly, these assays, by design, depend on a 
functional change of the reporter gene product and may not respond to all newly induced 
genetic alterations.  For example, the X-chromosome location of the HPRT gene makes it 
relatively insensitive to large deletions affecting the entire chromosome, as such events tend 
to be lethal to the cell due to the hemizygous nature of the X-chromosome.  The X 
chromosome location also prevents detection of mutations that occur by mitotic 
recombination; these events can be detected by autosomal genes such as tk.  Thus, the HPRT, 
TK and XPRT mutation tests detect different spectra of genetic events. Another limiting factor 
of the currently used mammalian cell mutation assays is their reliance on an externally 
supplied metabolic activation system (such as liver homogenate preparations) to detect pro-
mutagens. Furthermore, unless extensive molecular and banded karyotypic evaluation is 
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conducted on the mutants, the current assays provide little information on the underlying 
mechanism that resulted in the induction of a mutation.  
The IWGT sub-group on Novel & Emerging In Vitro Mammalian Cell Mutagenicity Test Systems 
examined the literature to identify new approaches for mutation detection, which  show 
promise for their application in hazard identification.  The focus of this sub-group was assays 
that were not covered by the other three sub-groups (e.g., in vitro Pig-a, transgenic cell lines, 
and improving existing assays using TK6 cells).  Only assays that anchored the measured 
endpoint to DNA sequence changes were considered in this review; those indicator assays 
that only measured DNA damage signalling were excluded from consideration as they do not 
measure bona fide mutational events.  
 
2. Materials and methods  
The literature search undertaken for this review utilised the PubMed  
(www.ncbi.nlm.nih.gov/pubmed) and Web of Science databases 
(http://www.webofknowledge.com/). Initially the following key words were used as search 
terms:  
 Trinucleotide repeat instability AND mutation 
 Haploid cell line mutation 
 Next generation sequencing mutation screen* 
 Mutation detection AND flow cytometry 
 Reporter mutation detection OR screen* 
 Haploid transposon (HTP) screening 
 Mutation detection 
 Intragenic mutations 
 Transgenic reporter genes AND mutation 
 Transgenic shuttle vectors AND mutation 
 PiggyBac Transposon AND mutation 
 transposon mutant libraries 
 Single-molecule PCR analysis (SM-PCR) AND mutation 
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 Expanded simple tandem repeats (ESTRs) AND mutation 
 Trinucleotide microsatellites AND mutation 
 Trinucleotide repeat mutagenesis 
 Microsatellite mutation 
 Tandem-repeat mutations 
 Transgenic rodent mutation reporter (TGR) 
 Characterization of mutation rate 
 Haploid gene-trap mutants 
 Human isogenic cell line 
 Chemically induced microsatellite mutations 
 Mutation reporter screen  
 Sensitive small pool PCR (SP-PCR) AND mutation 
 GFP Reporter AND mutation 
 
*- Truncation search term.   
 
Using these search terms 96,968 papers were identified in the databases, the vast majority of 
them considered irrelevant as they were unrelated to the subject matter of the literature 
search. Focus was placed on identifying articles that demonstrated novel techniques or 
potentially novel techniques for undertaking mammalian cell mutagenicity testing in vitro. 
Moreover, articles that focused on techniques under investigation by the other IWGT sub-
groups were disregarded to avoid duplication. To narrow the focus to more relevant 
publications, a second search was conducted using a more restrictive set of terms. These 
terms were selected with the aim of narrowing the search focus to novel in vitro mammalian 
cell mutagenicity assays, whilst avoiding inclusion of articles using already established test 
systems and / or tests that were unrelated to mutation screening. The refined set of search 
terms used included the following: 
 
 Haploid cells AND Mutation  
 Mutation reporter screen  
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 Next generation sequencing reporter screen 
 Trinucleotide repeat instability AND mutation  
 
3.  Results and discussion  
 
The final, refined search using the four terms defined in the Methods section resulted in the 
identification of 3707 papers of which a total of 3684 were discarded. Papers were discarded 
if they were irrelevant (i.e. not applicable for application as an in vitro mammalian cell 
mutagenicity assay),were not based in mammalian systems (e.g. instead the publications 
focused on other organism such as plants, aquatic organisms, or microorganisms) or if they 
involved the currently used gene mutation assays (i.e. established mutation reporter assays 
that are already applied in the genotoxicity testing field). Additionally, it is important to note 
that an opportunity to utilise reporter screens that signify DNA damage has arisen following 
exposure to an exogenous agent. For example, the ‘Anthem’s Genotoxicity Screen’ was 
developed to highlight the presence of increased DNA damage through the evaluation of p21, 
GADD153 and p53 reporter gene activity in response to genotoxic agents [2]. Although these 
test systems detect DNA damage signals, this does not directly mean that a mutagenic event 
has arisen.  DNA damage signals are often induced in extensively damaged cells that may 
undergo either DNA repair or apoptosis. Thus, such report assays are not specifically mutation 
detection systems. Consequently, they were not considered further in this review as they are 
not capable of evaluating the induction of mutagenic events.   
 
For each of the four-selected search terms, the total number of hits, number of papers 
discarded and number of papers selected for further evaluation are highlighted in Table 1.  
Additionally, a contextual summary of each of the papers selected for review is provided in 
Table 2, coupled to a brief outline on how the techniques might be used for hazard 
identification and the advantages and/or disadvantages of each of the approaches. 
   
Within Table 2 the papers selected for this review were grouped into three categories: 
genome-wide loss-of-function screening tools, next-generation sequencing (NGS) mutation 
screens and fluorescence-based mutation detection methods. Papers within the genome-
wide loss of function category were based either on haploid cell or Clustered Regularly 
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Interspaced Short Palindromic Repeats (CRISPR) studies. The haploid studies have not directly 
been utilised for chemical mutagenicity screenings. However, they  demonstrate the potential 
of using haploid cells for this purpose as they contain a single gene and thus, mutation in this 
reporter gene would result in measurable phenotypic change [3-8]. This would therefore offer 
possibilities for mutagenicity screening, including reverse mutation assays or analysis of a test 
compounds effect on a gene of interest. The CRISPR studies that were evaluated had not been 
directly applied to mutagenicity screening, but they show the potential for creating libraries 
of mutant cells and the isolation of specific mutants [9, 10]. The use of such a system for 
mutagenicity screening following exposure to an exogenous agent is questionable, as the 
methodology would require significant adaption for this application.     
Perhaps the most promising of the three categories within Table 2 is use of NGS [11-16]. NGS 
technology can potentially permit high throughput genome wide mutation detection and the 
power to provide supporting linkage between a mutation signature with the genotoxic 
agents’ mode of action (MoA) through identification of changes characteristic to specific 
MoAs. However, a significant issue with this technique at present is the high error rate 
associated with the sequencing procedure which would reduces the ability to detect 
mutations occurring at very low frequencies. NGS error rate varies, depending on the 
technical approach used; for example, the PCR copy consensus assay-based techniques Safe-
Sequencing system (Safe-SeqS) and the Duplex sequencing method have error rates of 2.0 x 
10-4 and 2.5 x 10-6 errors/base pairs (bp) respectively [11, 17, 18]. Both Safe-SeqS and duplex 
sequencing are capable of identifying low abundance mutations. However, they have low 
effective coverage because of redundant PCR amplification due to superfluous DNA 
replication. In comparison circle sequencing, whereby genomic DNA fragments are amplified 
by rolling circle amplification has an error rate of 7.6 x 10 -6 /bp [11, 19, 20]. Circle sequencing 
offers the advantage that the original DNA molecule is the only template, therefore possible 
errors are not amplified further. Both rolling circle amplification and PCR copy consensus 
assays are techniques that can detect point mutations. In order to undertake analysis of 
genome structural variations induced by a clastogenic agent methodologies need to be used 
that can identify junctions of genome fragmentation [11]. Typically, this can be achieved by 
the breakpoint being detected in overlapping reads at that locus. This requires sequencing of 
multiple cells and therefore would be highly expensive. Regardless of the NGS approach 
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undertaken the methodology cost can be very high, making dose-response analysis 
expensive. Nonetheless, it is notable that the cost of NGS is continually falling and there is 
extensive effort currently underway to minimise the error rate. Thus with future 
development, NGS techniques offer significant promise as an emerging mutation detection 
tool that could be applied in genotoxicity assessments.  
The final category was dedicated to test systems that utilised fluorescence-based mutation 
detection methods, typically reliant on the activation of the green fluorescent protein (GFP) 
gene when a mutation is induced  [21-26]. This fluorescence-based technique typically detects 
a frame shift mutation that consequently places the GFP gene into an open reading frame, 
thus allowing the detection of GFP by high throughput analysis equipment such as flow 
cytometry. Despite the speed of analysis and the large numbers of samples that could readily 
be evaluated in a short space of time, there are some potentially significant disadvantages to 
this category of techniques.  Firstly, they rely on the integration of plasmids into host cells; 
given that transfection efficiencies of mammalian cells vary substantially, the reproducibility 
of data generated in such vector-based systems may be severely compromised. Secondly, the 
methodology would only be able to detect mutagenic events that shifts the GFP protein into 
the open reading frame, thus mutagenic events  that do not impact the reading frame would 
be undetectable.  
 
4. Recommendations and Future Outlook 
Our search identified an array of technologies that are currently used to detect and analyse 
mutation and that are being applied in a variety of different contexts.  However, none of these 
new approaches have been developed or are currently readily applicable for routine hazard 
identification.  While these approaches demonstrate significant promise, particularly the NGS 
approaches, they require substantial development before they can be applied to evaluate the 
induction and characterisation of mutation for genotoxicity testing purposes. It should also 
be noted that none of the technologies discussed address the issue of reliance of in vitro 
methods on exogenous metabolic activation.  It is also important to discriminate between a 
regulatory-driven test system versus a model for use in research mode as the requirements 
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can be very different when considering the demands required for routine safety assessment 
as opposed to hypothesis testing.  
The IWGT Workgroup extensively discussed and reached consensus on the following features 
that would be needed for an ideal mutagenicity test system for safety assessment: 
1. Novel test systems should ideally report on a wide array of heritable mutagenic 
changes manifested throughout the genome and cover the full spectrum of genetic 
events induced by substances with a broad range of modes of action. 
2. Although not absolutely necessary for hazard identification as it is currently defined, 
it would be of substantial benefit if tests are able to detect mutations that result in 
disease-related phenotypes. However, assessment of overall mutational load also has 
value.  
3. There is increasing evidence that mutations in non-coding regions can have a negative 
impact on cell function (e.g. transcription factor binding site disruption) and are 
associated with human disease and cancer. Therefore, test systems are needed that 
would include the identification of mutations in non-coding regions.   
4. New mammalian cell mutation test systems must be able to accurately and reliably 
detect and quantify rare events. Accuracy and reliability would need to be carefully 
validated. 
5. Ideally, novel test systems should be metabolically competent, thus, avoiding the 
necessity for exogenous metabolic activation. Nevertheless, the limitations of any in 
vitro system, relative to in vivo conditions, kinetics and dynamics, must be 
acknowledged. Novel test systems that are able to recapitulate in vivo complexity will 
likely yield improvements in predictive capacity for hazard assessment. 
6. Hazard screens that have the capacity to be high throughput would be of great benefit, 
but this needs to be balanced against the cost effectiveness of the technology as high 
cost would likely retard adoption and implementation. 
 
Despite the emergence of novel methods for identifying mutation, the new tests available are 
not currently in a position to move into routine safety assessment use. However, with future 
research to tailor the application of some of these exciting developments in the mutagenicity 
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testing arena, the advent of new technologies such as NGS will no doubt have an important 
role to play in regulatory hazard screening of the future.  
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Table 1- Total number of papers identified, discarded and selected when chosen search 
terms were inputted into the PubMed and Web of Science databases 
 
Search term  Total number of hits  Number of papers 
discarded  
Number of papers 
selected for review  
Haploid cells AND 
Mutation 
2528 2521 7 
Mutation reporter 
screen  
502 498 4 
Next generation 
sequencing reporter 
screen  
17 10 7 
Trinucleotide repeat 
instability AND 
mutation  
660 655  5 
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Table 2 – Context and summary of papers identified within horizon scan for novel & emerging in vitro mammalian cell mutagenicity test systems    
 
Paper 
Reference  
Context of use & 
cell type 
Paper summary  Chemical 
tested (if 
any)  
How to apply to 
mutagenicity testing 
Advantages and 
disadvantages  
Genome-wide loss-of-function screening tools (Haploid cells and RNA interference)  
Wutz, 2014a[3] Introduction to 
what haploid cells 
are.  
 
Description of the development of 
haploid cells and their potential use. 
N/A Almost all the papers in 
this category (haploid cell 
studies and CRISPR 
application) were aimed at 
genome-wide loss-of-
function screening to 
support phenotype 
analysis.  
Although the haploid 
papers do not directly 
undertake chemical 
mutagenicity screenings, 
they do demonstrate the 
potential of using haploid 
cell lines in particular for 
this purpose. By using 
haploid cells, a mutation 
Advantages – 
Haploid cells allow for 
phenotypic analysis 
which cannot be 
compensated by a copy 
of the gene. 
Clonal selection of 
mutants is not required. 
Disadvantages –  
To date neither haploid 
cells nor CRISPR has 
been applied to 
mutagenicity screening.    
 
Wutz, 2014b 
[4] 
Introduction to 
what haploid cells 
are (2).  
Discussion on haploid development in 
animals, haploid mammalian embryos, 
mammalian haploid embryonic stem cells, 
developmental potential of haploid cells, 
haploid cells in tumours, application of 
haploid cells for genetic screens.  
    
N/A 
Bürckstümmer 
et al, 2013 [5] 
 
Creation of a library 
of mutant haploid 
cells that could be 
used for illustrating 
The study created a library of mutant 
haploid cells with a gene-trap retrovirus. 
Using this library, a clone was identified 
that has a disruption to the TNFRSF1A 
N/A  
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gene function by 
their phenotypes.  
KBM7 - stable near-
haploid cell line 
subcloned from a 
CML patient sample 
containing the BCR-
ABL1 gene fusion. 
 
gene which encodes for the TNF receptor. 
The cells therefore would no longer 
respond to TNF stimulation and were 
unable to undergo TNF induced 
apoptosis. 
which directly leads to a 
phenotypic change cannot 
be compensated for by a 
second copy of the gene 
(as in diploid cells). This 
offers various possibilities 
for mutagenicity screening 
such as isolation of 
mutants for reverse 
mutation screenings or 
direct analysis of the effect 
of the test compound on a 
particular gene/pathway of 
interest.   
The CRISPR papers 
demonstrate the potential 
to create libraries of 
mutant cells and isolation 
of specific mutants, but 
this may be less useful for 
detecting random 
mutagenicity events 
required for genotoxicity 
screens.      
Methods may not be 
high throughput.  
 
Pettitt et al, 
2013 [6]  
 
Creation of a large 
haploid library of 
random mutants by 
piggyBac 
transposon 
mutagenesis.   
Mouse embryonic 
stem cells 
This study created a library of haploid 
mutants using piggyBac transposon 
mutagenesis.   
The library was tested by the exposure to 
6-thioguanine which allowed 
identification of mutations in the DNA 
mismatch repair pathway.  
The study also isolated PARP1 mutants 
which were subsequently used to identify 
the role of PARP1 in olaparib toxicity.     
 
N/A  
Rong et al, 
2015 [7] 
 
Human haploid cells 
mutagenized by 
integration of gene 
trap vectors to 
Mutagenized haploid cells were treated 
with a bacterial pore-forming toxin, 
aerolysin, which binds to GPI-anchored 
proteins for targeting to the cell 
N/A 
 17 
identify genes 
required for GPI 
biosynthesis.  
Human HAP1 cells 
derived from 
haploid KBM7 cells 
(CML haploid cells) 
 
membrane. Cells that showed low surface 
expression of CD59, a GPI-anchored 
protein, were further enriched for. 
This screen identified 23 gene regions 
that when mutated are expected to 
decrease surface expression of GPI anchor 
proteins. 
 
Tokunga et al, 
2014 [8] 
 
Use of haploid 
mouse ESCs for 
identification of 
mutants defective 
in steps of the GPI-
anchor biosynthetic 
pathway 
The study mutagenized ESCs with N ENU. 
Then a phenotypic screen of mutants 
defective in different steps of the GPI-
anchor biosynthetic pathway that results 
in an alpha-toxin resistant phenotype, 
was conducted.  
The investigation identified 115 mutant 
alleles that were defective in the pathway 
using this technique.   
 
ENU (0.25 or 
0.2 mg/ml 
for 2h) to 
induce 
mutation for 
phenotypic 
screening for 
loss-of-
function 
mutants. 
Koike-Yusa et 
al, 2014 [9] 
Use of CRISPR-
associated systems 
to introduce 
genome wide- 
targeted mutations 
in mouse ESCs. 
This study created a large mouse 
genome-wide lentiviral CRISPR gRNA 
library to express 87897 gRNAs targeting 
19150 mouse protein coding regions. This 
produced genome-wide 
N/A 
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mutant mouse ESC libraries that were 
used for recessive screens using alpha-
toxin and 6-thioguanine, which identified 
4 unknown genes involved in the 
resistance to these treatments.  
 
Wang et al, 
2014 [10] 
Loss-of-function 
genetic screening 
approach for 
positive & negative 
selection using a 
genome-scale 
lentiviral sgRNA 
library. 
KBM7 cells & HL60 
cells (a pseudo-
diploid human 
leukemic cell line). 
CRISPR-Cas9 system was used to create a 
mutant library in two human cell lines. 
These were subsequently screened by 
exposure to 6-thioguanine to identify 
expected members of the DNA mismatch 
repair pathway.  
N/A 
Next generation sequencing (NGS) mutation screens  
Maslov et al, 
2015 [11] 
Review paper 
discussing the 
application of NGS 
for genotoxicity 
testing.  
Paper discusses potential NGS approaches 
for mutation screening, the pitfalls of the 
technique and what we need to 
overcome with further research to move 
N/A NGS based techniques 
are not widely used in 
the genetic toxicology 
field. This technology 
potentially offers strong 
Advantages-  
 
Enables direct analysis 
of DNA in s genome 
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the use of NGS in mutagenicity testing 
forward. 
 
power to enable 
genome wide detection 
and characterisation of 
mutation. Additionally, 
it has the power to 
provide data supporting 
the linkage between 
mutational signatures / 
profiles with a 
genotoxic agents’ MoA. 
However, technological 
advances that bring 
down cost and enable 
discrimination between 
background de novo 
mutations and 
chemically induced rare 
events to measure low-
abundance somatic 
mutation are still 
required. 
 
wide manner with single 
nucleotide resolution. 
Mutations are fully 
characterised; provides 
mutational signatures to 
understand MoA. 
There is no dependency 
on any particular 
gene/cell line. 
Automation and high 
throughput analysis are 
possible. 
Disadvantages-  
High error rate 
associated with the 
sequencing procedure 
(e.g. PCR amplification 
error). This reduces 
sensitivity and 
confounds the detection 
of mutations in low 
abundance. 
In genetic toxicology, 
the mutations are 
typically random; there 
Poon et al, 
2014 [12] 
Review paper that 
discusses mutation 
detection in human 
tumours using NGS. 
 
Paper discusses mutation signatures in 
human tumours, the value of 
characterising those signatures by NGS 
and implications for surveillance and 
prevention of cancer. 
The authors state that they ‘envision 
development of a wide-ranging 
compendia of mutation signatures from 
tumours and a concerted effort to 
experimentally elucidate the signatures of 
a large number of mutagens’.   
 
N/A 
Wang et al, 
2016 [13] 
Development of an 
ultra-sensitive NGS 
platform called 
“Easy Mutation 
Frequency 
detection platform” 
(“EasyMF”) and 
incorporating it 
with a widely used 
supF shuttle vector-
The paper’s sequencing technique was 
developed to analyse low frequency 
mutations caused by DNA damage 
treatments. This was undertaken by 
transfecting a UV damaged plasmid into 
human 293T cells and allowing replication 
to occur. The mutations were amplified 
and identified by NGS. Emphasis was 
placed investigating mutations in the Poln 
and REV1 genes  
UV (220 J/m3, 
plasmid 
exposure time 
not given) 
Average 
mutation 
frequency was 
1.0E-04 
 
 20 
based mutagenesis 
system. 
REV1 knocked 
down and Polη 
knocked down 293T 
cells (human 
embryonic kidney 
cells) 
 
 is a need to discriminate 
among cellular 
heterogeneity, 
spontaneous mutations 
and chemically induced 
mutation. 
Sequencing costs can be 
very high making routine 
dose-response analysis 
expensive.  
Wright et al, 
2016 [14]  
Use of an NGS 
method based on 
amplicon 
sequencing for 
mutant analysis 
during cell line 
development.  
CHO cells 
 
This study developed a method for the 
identification of genetic mutations in 
cloned CHO cells expressing a 
biotherapeutic protein. Total RNA was 
isolated from cell samples, cDNA 
amplified and subsequently analysed by 
NGS.  
  
N/A 
Zhang et al, 
2015 [15] 
In this study, the 
authors explored 
the use of RNA-
sequence 
technology (NGS) 
for the 
characterization of 
To cause an increase in cell mutation rate 
CHO cells were culture with a mitogenic 
selection reagent, methotrexate, prior to 
sequencing. Analysis of the heavy chain 
and light chain of the mAb was 
undertaken, coupled to use of GAPDH as 
the house keeping gene. When cells were 
Methotrexate 
(0, 20 or 80 nM 
for 3-4-day 
passage period) 
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the mutation rate in 
a stably transfected 
CHO cell line 
expressing a 
recombinant 
monoclonal 
antibody (mAb) 
under extensive in 
vitro passaging. 
 
sequenced the study noted an elevated 
mutation rate with increasing passage 
number when 80nM methotrexate was 
applied. 
 
Getta et al, 
2017 [16] 
Study that uses NGS 
to detect mutations 
in leukaemia 
patient bone 
marrow. 
The study compared a 28 panel NGS 
technique for mutation identification with 
the more commonly used multi-
parameter flow cytometry technique.  
The paper stated that by using a 28 NGS 
panel their study allowed broad coverage 
of known mutation hotspots and a 
median number of 2 mutations was 
detected in patients at diagnosis. 
 
N/A 
Fluorescence-based mutation detection methods 
Dobrovolsky et 
al, 2002 [21]  
Development of a 
double transgenic 
CHO cell line that 
contains: Plasmid 1) 
The double transgenic cells were treated 
with gamma-radiation, MNU or MMS. If a 
mutation occurred in the repressor gene 
and no functional repressor was 
Gamma-
radiation 
(400, 500, 
800rad); 
Fluorescence based assays 
for mutation detection 
offer the opportunity for 
high throughput analysis 
Advantages-  
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coding for GFP 
under the control of 
a Tet-responsive 
promoter that 
contains 
repressor-binding 
operator 
sequences; and 
Plasmid 2) Tet-
repressor. 
 
synthesized, the cells expressed GFP. 
Mutation events were therefore 
measured by FACS. Due to the nature of 
the technique only large-scale mutations 
were detectable.  
Generally, the mutation frequency data 
were not clear cut. Issues with low / 
variable cloning efficiency could affect 
sensitivity, specificity and reproducibility. 
MNU 
(200µM); 
MMS 
(750µM) 
 
 
following treatment with a 
potential mutagen. These 
techniques rely on the 
activation of a GFP gene 
following a mutagenic 
event such as a frameshift 
mutation in a tri/quad 
nucleotide repeat that 
shifts the gene into the 
open reading frame.  
These techniques may be 
unable to detect small 
mutagenic events such as 
point mutations, but show 
promise as a screening 
tool.  
Potential for high 
throughput analysis. 
Disadvantages-  
These techniques rely on 
the transfection of 
plasmids and their 
integration into the 
genome of host cells. 
There may therefore be 
variability with cloning 
efficiency that would 
affect sensitivity and 
specificity. 
Only able to detect 
mutagenic events that 
shift the GFP gene into 
an open reading frame, 
therefore would be 
unable to detect small 
mutagenic events.  
Chatterjee, et 
al, 2015 [22] 
 TNR mutagenesis 
was used to assess 
mutation events 
induced by 
environmental 
stress.   
GFP(CAG)89 cells 
derived from T-REx 
HEK293 cells 
This study aimed to investigate if 
environmental stress induced 
mutagenesis in TNRs in human 
GFP(CAG)89 cells derived from T-REx 
HEK293 cells. These cells carry a 
chromosomal mini-gene with a CAG89 
tract repeat in the middle of it. If a 
mutation of this tract repeat is induced it 
will cause robust expression of GFP that 
can be measured by FACS.   
During the study cells were exposed to 
heat, cold, hypoxia or oxidative stress and 
the frequency of GFP+ cells quantified by 
FACS.  
Heat, cold, 
hypoxia or 
oxidative 
stress 
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The study demonstrated that 
environmental stress was capable of 
inducing mutations in CAG repeats.  
 
Chatterjee et 
al, 2016 [23] 
This is a follow on 
from the previous 
Chatterjee paper to 
assess the 
mechanism of 
environmentally 
induced TNR 
mutagenesis.   
The study used the same assay in [22] to 
investigate which DSBR pathways might 
play a role in environmental stress-
induced TNR mutagenesis. The 
investigation demonstrated that a knock 
down of alt-NHEJ components XRCC1, 
LIG3, and PARP1 suppresses stress-
induced TNR mutagenesis. 
 
N/A 
Healy et al, 
2006 [24]  
Flow cytometric 
detection of 
tandem repeat 
mutations induced 
by various chemical 
classes 
Embryonic murine 
C3h10t1/2 cells and 
DNA mismatch 
repair (MMR) 
proficient 
embryonic 
To facilitate detection of genotoxicity 
from environmental mutagen exposure, 
this study generated an in vitro enhanced 
GFP reactivation assay that quickly and 
effectively detects frameshift mutations 
in tandem repeat sequences. 
Two cell lines (C3h10t1/2 and MC2a) 
were transfected with GFP reporter 
plasmids which contain an out of frame 
GFP sequence. A frameshift mutation in 
these sequences consequently results in 
GFP revertants, which can be quantified 
H2O2 (0, 
0.001, 0.01, 
0.1 or 1 mM 
for 1h);  
TPA (0, 100, 
325,650, or 
1325 nM for 
48h);  
BPDE (0, 0.5, 
1, 2 or 3 M 
for 1h);  
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fibroblast cell line 
MC2a 
by FACS.  
The cell lines were treated with H2O2, 
TPA, BPDE, ENU, 9AA and two controls: 
acetone and ethanol. All chemicals 
induced an increase in GFP revertants, 
with the assay responding to a range of 
classes of mutagenic and carcinogenic 
compounds. The responses were not 
linked to cytotoxicity.  
 
ENU, 9AA (0, 
2, 8 or 16 
M for 4h) 
 
Slebos et al, 
2002 [25] 
Mutation induction 
in tetranucleotide 
repeats. 
Human colorectal 
carcinoma cancer 
cell line RKO 
The main goals of this study were to 
assess the effects of DNA damage on 
mutation frequency in microsatellite 
sequences and to determine any 
sequence-specific responses to DNA 
damage that may explain sporadic 
microsatellite mutations observed in 
carcinogen- related human cancer. Using 
the GFP reporter assay the study 
demonstrated that DNA damage can 
differentially increase the number of 
these mutations, depending on the agent 
and on the microsatellite repeat unit. 
RKO cells were transfected with plasmids 
containing microsatellite repeat units that 
shift the reading frame of the GFP 
Gamma 
irradiation (5 
Gy/min for 1 
min or 10 
Gy/min for 1 
min);  
MNNG (5, 
25, 50 M 
for 1h);  
t-butyl 
hydrogen 
peroxide 1, 
2, 3 mM for 
1h);  
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downstream. This allowed for detection 
of microsatellite slippage mutations 
induced by several DNA-damaging agents 
via quantification of GFP revertants using 
FACS. 
RKO cells were subsequently treated with 
gamma irradiation, BPDE, MNNG, t-butyl 
hydrogen peroxide, and UV irradiation 
and assayed for GFP-positive cells 48 h 
later. All mutagenicity tests induced 
increased GFP positive cells.  
 
BPDE (0.5, 1, 
2 M for 
1h); 
UV 
irradiation 
(15, 60 and 
100 J/m3 
exposure 
time not 
given) 
Santillan et al, 
2014 [26] 
Use of GFP-based 
fluorescence assay 
for the assessment 
of CAG repeat 
instability. 
 
T-Rex 293 cells 
The study describes a GFP-based 
fluorescence assay for assessment of CAG 
promoter repeat instability. The assay 
exploits an engineered intronic CAG 
repeat tract that interferes with 
expression of an inducible GFP mini-gene. 
GFP function was impaired by repeat 
expansion in a length- dependent 
manner. The intensity of fluorescence 
varies inversely with repeat length, 
allowing estimates of repeat tract 
changes in live cells. 
T-Rex 293 cells were transfected with the 
GFP-Pem plasmid with a CAG89 repeat 
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tract. CAG repeat instability was 
subsequently induced with doxycycline 
allowing for assessment between repeat 
length and GFP fluorescence. CAG repeats 
were also cleaved by the addition of zinc 
finger nuclease. The fluorescence assay, 
however, offers the possibility of directly 
detecting CAG repeat expansions. 
 
TNFRSF1A = tumour necrosis actor receptor superfamily member 1A, TNF = tumour necrosis factor, CML = chronic myeloid leukaemia, BCR-ABL1 = breakpoint 
cluster region Abelson proto-oncogene, PARP1 = poly adenosine diphosphate –ribose polymerase 1, GPI = glycosylphosphatidylinositol, ESCs = embryonic 
stem cells, ENU = N-ethyl-N-nitrosourea, gRNA = guide ribonucleic acid, sgRNA = single guide ribonucleic acid, UV = ultraviolet light, CHO = Chinese hamster 
ovary cells, mAb = monoclonal antibody, MoA = Mode of action, MNU = N-methyl nitrosourea, MMS = methyl methane sulphate, FACS = fluorescence-
activated cell sorting, TNR = trinucleotide repeats, alt-NHEJ = alt-nonhomologous end joining, DSBR = double stranded break repair, H2O2 = hydrogen peroxide, 
TPA = 12-O-tetradecanoyl-phorbol-13-acetate, BPDE = benzo-a-pyrene-diol-epoxide, 9-AA = 9-aminoacridine, MNNG = N-methyl-N-nitro-N-nitrosoguanidine, 
GFP = green fluorescent protein. 
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